5/8/2025

Bio-Techne Corp. stock outperforms competitors on strong trading day

Source: MarketWatch

5/8/2025

Kytopen Corp., a leader in providing continuous flow cellular engineering technologies and Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools today announced a partnership aimed at streamlining gene delivery solutions for the development and manufacture of advanced cell therapies. The collaboration will focus on the synergies developers can achieve by utilizing the TcBuster™ GMP non-viral genome engineering system and the Flowfect Tx™ GMP cellular

Source: Yahoo

5/8/2025

Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Source: Yahoo

5/8/2025

Kytopen Corp. and Bio-Techne Corporation announced a partnership aimed at streamlining gene delivery solutions for the development and manufacture of advanced cell therapies. The collaboration will...

Source: Finnhub

5/8/2025

Bio-Techne Corp (TECH) reports a 6% organic revenue increase and robust performance in protein sciences, despite facing macroeconomic uncertainties and tariff impacts.

Source: Yahoo

5/8/2025

Q3 2025 Bio-Techne Corp Earnings Call

Source: Yahoo

5/7/2025

TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.

Source: Yahoo

5/7/2025

Mairs & Power, an investment advisor, released the “Mairs & Power Balanced Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market reached a record high in February. However, tariff uncertainty in March led to a fall in equities, while fixed income benefited from perceived safety. The […]

Source: Yahoo

5/7/2025

Investors need to pay close attention to TECH stock based on the movements in the options market lately.

Source: Yahoo

5/7/2025

Life sciences company Bio-Techne (NASDAQ:TECH) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 4.2% year on year to $316.2 million. Its non-GAAP profit of $0.56 per share was 10.4% above analysts’ consensus estimates.

Source: Yahoo

5/7/2025

Bio-Techne Corporation (NASDAQ:TECH) Q3 2025 Earnings Conference Call May 7, 2025 9:00 AM ETCompany ParticipantsDavid Clair - Vice President-Investor...

Source: SeekingAlpha

5/7/2025

Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025.

Source: Yahoo

5/7/2025

Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Source: Yahoo

5/7/2025

Bio-Techne on Wednesday beatWall Street estimates for third-quarter profit, driven by growthin its unit that provides proteins, antibodies and otherproducts for research and said it is launching a...

Source: Finnhub

5/7/2025

S&P 500 Futures Rise in Premarket Trading; Sarepta Therapeutics, OneStream Lag

Source: MarketWatch

5/7/2025

Bio-Techne Corporation reported earnings results for the third quarter and nine months ended March 31, 2025. For the third quarter, the company reported sales was USD 316.18 million compared to USD...

Source: Finnhub

5/7/2025

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025,...

Source: Finnhub

5/6/2025

Bio-Techne Corp. stock underperforms Tuesday when compared to competitors

Source: MarketWatch

5/6/2025

ScaleReady, in collaboration with Wilson Wolf, Bio-Techne Corporation and CellReady, today announced that A2 Biotherapeutics, Inc. ("A2") has been awarded a $300,000 G-Rex® Grant. A2's G-Rex® Grant will enable expeditious process development and qualification of a G-Rex-based production system and will enable A2 to evaluate G-Rex for manufacturing cell therapies.

Source: Yahoo

5/6/2025

Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results tomorrow before market hours. Here’s what you need to know.

Source: Yahoo